Bandaríkin - enska - NLM (National Library of Medicine)

sandoz inc - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with c

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced stage ovarian cancer of epithelial origin. small cell lung carcinoma. carcinoma of the head and neck. carcinoma of the testis. paediatric cerebral tumours. soft tissue sarcoma and neuroblastoma.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced stage ovarian cancer of epithelial origin. small cell lung carcinoma. carcinoma of the head and neck. carcinoma of the testis. paediatric cerebral tumours. soft tissue sarcoma and neuroblastoma.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced stage ovarian cancer of epithelial origin. small cell lung carcinoma. carcinoma of the head and neck. carcinoma of the testis. paediatric cerebral tumours. soft tissue sarcoma and neuroblastoma.

Bandaríkin - enska - NLM (National Library of Medicine)

hospira, inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin injection and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been prev

Bandaríkin - enska - NLM (National Library of Medicine)

teva parenteral medicines, inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously tr

Bandaríkin - enska - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - initial treatment of advanced ovarian carcinoma carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. secondary treatment of advanced ovarian carcinoma carboplatin injection is indicated for the palliative treatment of patients with ovar

Bandaríkin - enska - NLM (National Library of Medicine)

gland pharma limited - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - initial treatment of advanced ovarian carcinoma carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (seeclinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. secondary treatment of advanced ovarian carcinoma carboplatin injection is indicated for the palliative treatment of

Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - carboplatina - solução para perfusão - 10 mg/ml - carboplatina 10 mg/ml - carboplatin - genérico - duração do tratamento: longa duração

Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - carboplatina - solução para perfusão - 10 mg/ml - carboplatina 10 mg/ml - carboplatin - genérico - duração do tratamento: longa duração